Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis

Deborah A Driscoll, Joshua Salvin, Beatrice Sellinger, Marcia L Budarf, Donna M McDonald-McGinn, Elaine H Zackai, Beverly S Emanuel

Abstract
Deletions of chromosome 22q11 have been seen in association with DiGeorge syndrome (DGS) and velocardiofacial syndrome (VCFS). In the present study, we analysed samples from 76 patients referred with a diagnosis of either DGS or VCFS to determine the prevalence of 22q11 deletions in these disorders. Using probes and cosmids from the DiGeorge critical region (DGCR), deletions of 22q11 were detected in 83% of DGS and 68% of VCFS patients by DNA dosage analysis, fluorescence in situ hybridisation, or by both methods. Combined with our previously reported patients, deletions have been detected in 88% of DGS and 76% of VCFS patients. The results of prenatal testing for 22q11 deletions by FISH in two pregnancies are presented. We conclude that FISH is an efficient and direct method for the detection of 22q11 deletions in subjects with features of DGS and VCFS as well as in pregnancies at high risk for a deletion.

DiGeorge syndrome (DGS), a developmental field defect of the third and fourth pharyngeal pouches, is characterised by thymic aplasia or hypoplasia, absent or hypoplastic parathyroid glands, and conotruncal cardiac malformations. The aetiology is presumed to be heterogeneous. There have been reported cases of autosomal dominant, autosomal recessive, and X linked inheritance.1 Chromosomal abnormalities are not uncommon in patients with DGS. The majority of cytogenetically abnormal DGS patients initially reported had unbalanced translocations with monosomy 22pter→q11.2-11 More recently, using high resolution banding techniques, visible interstitial deletions of 22q11.2 (del(22)(q11.21q11.23)) have been identified in approximately 25% of DGS patients.12 On the basis of the cytogenetic abnormalities, it was hypothesised that the DiGeorge critical region (DGCR) lies within 22q11.12-13 Molecular studies have borne out this suggestion as we and others have shown that cytogenetically normal DGS patients have microdeletions of 22q11.15-18 Our initial study began to delineate the DGCR. This region, bounded by locus D22S75 (N25) proximally and D22S259 (pR32) distally, was consistently deleted in the first 14 DGS patients we studied.19

More recently, we and others have shown that patients with velocardiofacial syndrome (VCFS) also have deletions of this same region of 22q11.19-20 VCFS is an autosomal dominant disorder characterised by palatal abnormalities, cardiac defects, learning disabilities, and a typical facial appearance.21-23 The presence of features common to DGS, such as neonatal hypocalcaemia and decreased lymphoid tissue, in some patients with VCFS suggested that these two disorders might share a common aetiology and pathogenesis.24 Cytogenetic studies using high resolution banding techniques detected interstitial deletions of 22q11.2 in approximately 20% of VCFS patients.19 Molecular studies using either restriction fragment length polymorphisms (RFLP) or dosage analysis detected 22q11 microdeletions in the majority of patients reported by our group and others.18-20

Since our initial reports we have evaluated an additional 36 patients presumed to have DGS and 40 patients with the suspected diagnosis of VCFS to determine the prevalence of 22q11 deletions in association with these disorders. In addition, we have applied a fluorescence in situ hybridisation (FISH) assay using cosmids from the DiGeorge critical region (DGCR) to detect 22q11 deletions directly in patients as well as in pregnancies at risk for a deletion. In this report we describe the results of DNA dosage and FISH studies, discuss the implications for genetic counselling, and describe the application of FISH for the prenatal diagnosis of 22q11 microdeletion syndromes.

Materials and methods
Patients
Thirty-six patients with the presumed diagnosis of DGS and four parents of DGS patients with a 22q11 deletion were referred to our laboratory for molecular analysis. Forty patients with suspected VCFS were also analysed for evidence of a 22q11 deletion. Two cases were studied for prenatal diagnosis. Case 1. One of our previously reported, deletion positive VCFS patients (VCF-10)16 elected to have an amniocentesis during her second pregnancy. Amniocentesis was performed at 16 weeks gestation. Cultured amniocytes were obtained for DNA analysis as well as FISH. Case 2. The normal parents of a deletion positive VCFS patient requested that FISH studies be performed to exclude a 22q11 deletion in a subsequent pregnancy. This study was performed as an adjunct to routine cytogenetic studies performed for advanced maternal

Division of Reproductive Genetics, Department of Obstetrics and Gynecology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
D A Driscoll
Division of Human Genetics and Molecular Biology, Department of Pediatrics, The Children’s Hospital of Philadelphia, Philadelphia, PA 19104, USA.
J Salvin
B Sellinger
M L Budarf
D M McDonald-McGinn
E H Zackai
B S Emanuel
Correspondence to Dr Driscoll.
Received 16 June 1993.
Revised version accepted 10 July 1993.

813
by dosage, three by FISH, and three by both dosage and FISH.

**FAMILY STUDIES**
Molecular analysis of the parents of five probands; four with DGS and one with VCFS, showed a 22q11 deletion in one parent in each case (fig 1A–E). One of these parents was hemizygous at D22S75 and D22S259 by dosage analysis (fig 1D). FISH indicated hemizygosity at these loci in the remaining parents. Three parents had mild learning disabilities but no history of congenital heart disease, neonatal hypocalcaemia, immune deficiency, or palatal abnormalities (fig 1A–C). In addition to a learning disability, the mother of the fourth proband with DGS had a cleft palate (fig 1D). The parent of the child with VCFS also carries the diagnosis of VCFS; she has a cleft palate, learning disorder, and facial dysmorphism consistent with VCFS (fig 1E).

**PRENATAL STUDIES**

**Case 1**
DNA was obtained from the cultured amniocytes from the pregnancy at 50% risk for VCFS and the associated 22q11 deletion. Dosage analysis showed the presence of two copies of D22S75 (N25) in contrast to a single copy in both the affected mother and her affected daughter. FISH with an N25 specific cosmid confirmed the presence of two alleles in the fetus. Hence, the fetus did not appear to have inherited the maternal chromosome 22 bearing the deletion.

Fig 2A shows an example of metaphase chromosomes from the mother with VCFS after hybridisation with N25 and cos82 cosmids. The chromosomes 22 are identified with cos82 marking the distal long arm of both homologues. A hybridisation signal for N25 is visualised on only one of the chromosomes 22, consistent with a deletion. In contrast, in fig 2B, signals for both cosmids are seen on both chromosomes 22 of the at risk fetus. In addition to molecular studies, we recommended that a level II ultrasound examination and fetal echocardiogram be performed during the pregnancy to rule out a cleft palate and a congenital heart defect in the fetus. There were no apparent congenital anomalies seen on ultrasonography. The mother declined to have an echocardiogram. She was delivered of a normal appearing liveborn infant by spontaneous vaginal delivery at 36 weeks' gestation. There was no evidence of a palatal abnormality or facial dysmorphism. Dosage studies on DNA obtained from a sample of cord blood as well as FISH of peripheral blood lymphocytes confirmed the absence of a 22q11 deletion in the infant.

**Case 2**
FISH studies of metaphase chromosomes from the chorionic villus sample showed two copies of both D22S75 and D22S259. This finding was in contrast to results obtained in a
Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes

Figure 1 Pedigrees of the five familial cases (A–E).

Figure 2 Fluorescence in situ hybridisation with chromosome 22 cosmids. The cosmids were labelled with biotinylated-11-dUTP and visualised with fluoresceinated avidin. The chromosomes 22 are identified with cos82 marking the distal long arm and the test probe is a cosmid for N25, from the DGCR. (A) Metaphase chromosomes from mother affected with VCFS hybridised with cosmids cos82 and N25. A hybridisation signal for N25 is seen on only one of the chromosomes 22 which is consistent with a deletion. (B) Hybridisation of cos82 and N25 to metaphase chromosomes from her at risk fetus. A hybridisation signal for N25 is present on each chromosome 22.

study of the affected sib in whom we had previously shown a deletion of both loci. The pregnancy is continuing.

Discussion

Initial studies by our laboratory and others reported an association between DGS, VCFS, and 22q11 deletions. In these studies over 90% of the patients studied had either cytogenetically visible interstitial deletions or submicroscopic deletions of 22q11. We have examined an additional 76 patients with either DGS or VCFS to determine the prevalence of 22q11 deletions in these disorders. In the present study, 83% (30 of 36) of presumed DGS patients and 68% (27 of 40) of putative VCFS patients have 22q11 deletions. If we include the 14 DGS and 14 VCFS patients we previously reported, then deletions were detected in 88% of patients referred with a diagnosis of DGS and 76% with VCFS.

The percentage of affected patients with a 22q11 deletion is less than previously reported. If patients are included in the present study who do not have either DGS or VCFS, we may have underestimated the true prevalence of 22q11 deletions in these two groups of patients. It is of interest that the deletion appears to be more frequently detected in patients referred with the diagnosis of DGS. This may reflect the clinician's ability to diagnose DGS accurately in contrast to their ability to recognise VCFS.

The diagnosis of DGS is based on the presence of three findings: a congenital heart defect, hypocalcaemia, and a small or absent thymus. The clinical criteria for establishing a diagnosis of VCFS are not as restricted and it is likely that this study included patients in whom the diagnosis of VCFS was suspected but might not be corroborated. However, we relied on the clinical impressions of the referring geneticists and so the reported frequency of deletions in the population we present in this report may reflect the actual likelihood of detecting a deletion in clinical practice. The high frequency with which deletions were initially detected may reflect the small number of patients studied or the patient sample. The initial sample was derived from fewer clinicians and based on stricter inclusion criteria. Therefore, this study, which examines a large number of patients referred from numerous practising clinicians, provides us with a better estimate of the prevalence of 22q11 deletions in patients suspected to have DGS and VCFS.

The majority of patients appear to be deleted for the entire DiGeorge critical region (DGCR). We have not excluded the possibility that the non-deletion patients may have smaller deletions within the DGCR. Studies are in progress to determine whether these patients have deletions internal to the two markers (N25 and R32) used in this study. These disorders may also result from point mutations within critical genes in this region. As genes are identified, the non-deleted patients will be studied for the presence of point mutations.
Alternatively, another locus may be implicated, such as a locus on 10p. There have been several reports of 10p monosomy in association with DGS. Recently, molecular analysis of two DGS patients with cytogenetic deletions of 10p did not show a deletion of 22q11, suggesting that another locus is involved in the pathogenesis of DGS (unpublished results). Teratogens, such as retinoic acid and alcohol, and maternal diabetes have been associated with the DiGeorge anomaly. Molecular studies by our laboratory failed to detect a 22q11 microdeletion in two infants with DGS born to insulin dependent mothers, supporting the hypothesis that DGS is causally heterogeneous and that this represents a phenocopy of the 22q11 microdeletion syndrome.

Approximately 8% of the patients studied showed familial transmission of the 22q11 deletion. Deletions were detected in seven parents of patients with 22q11 deletions, five in this study and two in our previous report. Three parents were also diagnosed as having VCFS. However, three parents had only a learning disability or mild mental retardation and were only ascertained after the birth of an affected child. Such a mild phenotype may reflect which genes in 22q11 are deleted. As yet we have not detected a difference in the size of the deletion between numerous affected parents and their affected offspring. However, now that additional probes are available within and flanking the DGCR in 22q11, studies are in progress to identify the deletion boundaries in these families to determine if changes in the size of the deletion during meiosis accounts for the observed phenotypic differences. Phenotypic variability may also be explained by parent of origin of the deletion chromosome, genetic background, or in utero environment. We have recently identified highly polymorphic short tandem repeat polymorphisms in the DGCR which will enable us easily to examine the effect of parent of origin on the phenotype.

Recent studies suggest that several cytogenetically based disorders, such as Miller-Dieker and Wolf-Hirschhorn syndromes are better assessed for the presence of a microdeletion or cryptic translocation by FISH rather than routine cytogenetic analysis. We have established a FISH assay using cosmids for loci in the DGCR and have successfully used this assay to detect deletions in DGS and VCFS patients. Microdeletions of 22q11 have been detected in a total of 16 patients using FISH with cosmids specific for N25 and R32. FISH confirmed the results of dosage analysis in 10 patients, two with DGS and eight with VCFS. This highly sensitive assay eliminates the need for high resolution cytogenetic analysis to detect interstitial deletions of 22q11 in patients at high risk for a deletion.

In addition, we have shown the usefulness of FISH for prenatal testing for the detection of 22q11 deletions. FISH can be performed both on cultured amniocytes and chorionic villi. It does not require DNA extraction and time consuming Southern blotting necessary for dosage analysis. Hence, results are available faster. Traditionally, prenatal diagnosis of DGS and VCFS relied on ultrasonography and fetal echocardiography during the second trimester to detect the presence of a cleft palate or congenital heart defect. Detection of an affected fetus is limited by the ability to detect one of these features sonographically and, since the clinical features are variable, a normal sonogram would not definitively exclude the diagnosis of DGS or VCFS.

Patients with a 22q11 microdeletion who have a 50% risk of transmitting the deletion to their offspring can now be offered FISH for the prenatal detection of a 22q11 deletion as early as 10 to 12 weeks’ gestation by chorionic villus sampling (CVS). Although normal parents of offspring with a de novo deletion are presumably at a low risk for a recurrence in subsequent pregnancies, we have not excluded the small possibility of germline mosaicism for a 22q11 deletion in these persons. In the absence of studies to dispute this possibility, these families might consider prenatal testing for reassurance, as did the second family presented in this report.

We had previously suggested that molecular and cytogenetic evaluation of the fetus for a 22q11 microdeletion should be offered to the parents when a conotruncal heart malformation is detected prenatally. Recent studies have shown that 22q11 microdeletions occur in 20 to 30% of newborns with non-familial, isolated conotruncal cardiac malformations, including truncus arteriosus, interrupted aortic arch, and tetralogy of Fallot. These findings support our previous recommendation. These findings also suggest that, in addition to subjects with clinical features diagnostic of DGS and VCFS, persons with conotruncal heart defects need to be screened for 22q11 microdeletions to determine the aetiology of the disorder, identify other family members at risk for a deletion, and to assess the risk to their offspring.

Subjects with a 22q11 deletion have a 50% risk of transmitting the deletion to their offspring and should be offered genetic counselling. Furthermore, since the phenotype of the 22q11 microdeletion syndrome is variable, the fetus with a deletion is at risk for the spectrum of malformations seen in both DGS and VCFS. At present we are unable to predict the clinical outcome based on a deletion of the two markers used in the present studies. The correlation between the genotype and phenotype will require a detailed molecular analysis of the deleted region to determine which region or genes specify individual features of the phenotype.

The authors wish to thank Dr J Biegel for invaluable assistance with laboratory handling of patient specimens. We also thank G Lech and M Dunn for their technical assistance. This work was supported in part by NIH grants HD26979 and CA39926 and March of Dimes Birth Defects Foundation Basic Research grant 1-FY91-106.

1 Lammer EJ, Opitz JM. The DiGeorge anomaly as a de-
Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes

817

Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: implications for genetic counselling and prenatal diagnosis.

D A Driscoll, J Salvin, B Sellinger, M L Budarf, D M McDonald-McGinn, E H Zackai and B S Emanuel

J Med Genet 1993 30: 813-817
doi: 10.1136/jmg.30.10.813

Updated information and services can be found at:
http://jmg.bmj.com/content/30/10/813

Email alerting service
These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/